abstract |
The present disclosure relates to antibody-drug conjugates in which a modified antibody comprising a motif having a specific structure at the end of the antibody is conjugated to a drug via a linker and compositions comprising the same, and more In particular, it relates to a modified antibody-drug conjugate (mADC) and a composition comprising the same, the modified antibody-drug conjugate comprising a modified antibody, the modified antibody due to a group bound to the C-terminus of the heavy or light chain of the antibody sequence with significantly increased drug conjugation yields. |